Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2092 Injection in Healthy Participants
NCT07776041Phase 1Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1 trial of SYH2092 in obesity (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Treatment-related adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SYH2092
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07776041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776041.